| abstract |
This technology comprises specific sequences of interfering RNA having the capacity to negatively regulate the expression of the RNA coding for the receptor LOX-1. These sequences can be the nucleotide sequences corresponding to SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, or SEQ ID NO 5, as well as fragments of said sequences, which maintain the capacity to negatively regulate the expression of the RNA coding for the receptor LOX-1, or homologues of these sequences. The invention also relates to the use of these nucleotide sequences in the production of medicines that permit the blocking of the growth and progression of tumour cells in the prostate in a selective, effective and specific manner, permitting the mass administration of these nucleotide sequences in the area surrounding the tumour without affecting the healthy cells. |